Dongsung Pharm
Dong Sung Bio Pharm.Co.,Ltd. manufactures and sells pharmaceuticals and cosmetics in South Korea. The company offers over the counter drugs, such as emollient, vitamin supplement, alopecia treatment, antihistamines, liver disease treatment, fire extinguisher solvent, antiviral, eye drops, menopause treatment, sleep inducer, antipyretic, analgesic, anti-inflammatory, vascular reinforcement, broad-… Read more
Dongsung Pharm (002210) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.104x
Based on the latest financial reports, Dongsung Pharm (002210) has a cash flow conversion efficiency ratio of 0.104x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩4.20 Billion) by net assets (₩40.55 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Dongsung Pharm - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Dongsung Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Dongsung Pharm Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dongsung Pharm ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bionano Genomics Inc
NASDAQ:BNGO
|
-0.119x |
|
NextCell Pharma AB
ST:NXTCL
|
-0.162x |
|
J.S.P. Property Public Company Limited
BK:JSP
|
0.025x |
|
Airthings ASA
PINK:ARTGF
|
-0.038x |
|
Chonburi Concrete Product Public Company Limited
BK:CCP
|
0.074x |
|
Cadence Opportunities Fund Ltd
AU:CDO
|
0.000x |
|
IRLAB THERAP. AB A
F:6IRA
|
N/A |
|
Murray & Roberts Holdings Limited
PINK:MURSF
|
0.535x |
Annual Cash Flow Conversion Efficiency for Dongsung Pharm (2008–2024)
The table below shows the annual cash flow conversion efficiency of Dongsung Pharm from 2008 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩55.18 Billion | ₩-9.94 Billion | -0.180x | -67.06% |
| 2023-12-31 | ₩39.80 Billion | ₩-4.29 Billion | -0.108x | -18.93% |
| 2022-12-31 | ₩42.81 Billion | ₩-3.88 Billion | -0.091x | -53.08% |
| 2021-12-31 | ₩46.44 Billion | ₩-2.75 Billion | -0.059x | -164.99% |
| 2020-12-31 | ₩54.95 Billion | ₩5.01 Billion | 0.091x | +176.94% |
| 2019-12-31 | ₩70.10 Billion | ₩-8.31 Billion | -0.118x | -588.87% |
| 2018-12-31 | ₩57.48 Billion | ₩1.39 Billion | 0.024x | -13.40% |
| 2017-12-31 | ₩64.27 Billion | ₩1.80 Billion | 0.028x | +146.55% |
| 2016-12-31 | ₩55.62 Billion | ₩-3.34 Billion | -0.060x | -36.94% |
| 2011-12-31 | ₩60.20 Billion | ₩-2.64 Billion | -0.044x | -170.43% |
| 2010-12-31 | ₩59.10 Billion | ₩3.68 Billion | 0.062x | +184.40% |
| 2009-12-31 | ₩67.97 Billion | ₩-5.02 Billion | -0.074x | -1271.65% |
| 2008-12-31 | ₩67.82 Billion | ₩-365.26 Million | -0.005x | -- |